Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation.
about
Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Alemtuzumab as graft-versus-ho ...... cytomegalovirus reactivation.
@en
Alemtuzumab as graft-versus-ho ...... cytomegalovirus reactivation.
@nl
type
label
Alemtuzumab as graft-versus-ho ...... cytomegalovirus reactivation.
@en
Alemtuzumab as graft-versus-ho ...... cytomegalovirus reactivation.
@nl
prefLabel
Alemtuzumab as graft-versus-ho ...... cytomegalovirus reactivation.
@en
Alemtuzumab as graft-versus-ho ...... cytomegalovirus reactivation.
@nl
P2093
P2860
P1476
Alemtuzumab as graft-versus-ho ...... cytomegalovirus reactivation.
@en
P2093
B M Rezende
C B Resende
G M Teixeira
H Bittencourt
M M Teixeira
P T T Bernardes
P2860
P356
10.1590/1414-431X20165566
P407
P577
2017-02-09T00:00:00Z